sur B.R.A.I.N. Biotechnology Research And Information Network AG (isin : DE0005203947)
BRAIN Biotech AG Reports 2025 AGM Results and Strategic Milestones
On March 18, 2025, BRAIN Biotech AG held its annual general meeting, where all proposed agenda items received broad approval from shareholders. Notably, Dr. Anna C. Eichhorn and Stephen Catling were re-elected to the Supervisory Board. At the time of voting, 63.8% of the share capital was represented.
Dr. Michael Majerus, Chairman of the Supervisory Board, expressed satisfaction with the re-election of Dr. Eichhorn and Mr. Catling, highlighting their expertise as essential to the board. Over the past financial year, the company executed two significant transactions, enhancing its strategic development.
For the 2024/25 financial year, BRAIN Biotech AG forecasts a sales increase ranging from a high single-digit to low double-digit percentage, along with an adjusted EBITDA margin of around 10% in its core BRAINBiocatalysts segment.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de B.R.A.I.N. Biotechnology Research And Information Network AG